Moore Kelly, Stutzman Sonja, Priddy Laurin, Olson DaiWai
University of Texas Southwestern Harold C. Simmons Comprehensive Cancer Center.
University of Texas Southwestern Medical Center.
Clin J Oncol Nurs. 2019 Aug 1;23(4):411-416. doi: 10.1188/19.CJON.411-416.
Chemotherapy-related cognitive impairment refers to a cluster of symptoms commonly referred to as "chemobrain". To date, nursing literature on the progression of and tools used to evaluate chemobrain is limited.
The purpose of this pilot study was to explore the onset of chemobrain in patients who recently began chemotherapy treatment, as well as those who have been receiving chemotherapy for an extended period of time.
This prospective, nonrandomized, observational pilot feasibility study used the General Practitioner Assessment of Cognition and the Trail Making Test Parts A and B to examine chemotherapy-related cognitive impairment symptoms in patients undergoing chemotherapy treatment.
Paired t tests showed a significant difference in scores on the Trail Making Test Part A from baseline to eight months (p < 0.05) and in scores on the Trail Making Test Part B from four to eight months (p < 0.05). The mixed results suggest that the Trail Making Test Parts A and B may not be effective for testing chemotherapy-related cognitive impairment in patients.
化疗相关认知障碍是指一组通常被称为“化疗脑”的症状。迄今为止,关于化疗脑进展情况及用于评估化疗脑的工具的护理文献有限。
这项初步研究的目的是探究近期开始化疗的患者以及长期接受化疗的患者中化疗脑的发病情况。
这项前瞻性、非随机、观察性的初步可行性研究使用全科医生认知评估以及连线测验A和B部分来检查接受化疗的患者的化疗相关认知障碍症状。
配对t检验显示,从基线到八个月,连线测验A部分的分数有显著差异(p < 0.05),从四个月到八个月,连线测验B部分的分数有显著差异(p < 0.05)。混合结果表明,连线测验A和B部分可能对测试患者的化疗相关认知障碍无效。